Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy
Anti-tumor TSME combined with αPD-1 mAb may be a new strategy to improve the sensitivity of immune-resistant patients with advanced hepatocellular carcinoma to anti-PD-1 immunotherapy.
Authors
- Yangchen Liu (ORCID: https://orcid.org/0000-0003-0723-8743)
- Xinwei Guo (ORCID: https://orcid.org/0000-0002-8781-3340)
- Zhaoqun Deng (ORCID: https://orcid.org/0000-0003-0037-4697)
- Xiaoguang Wang (ORCID: https://orcid.org/0000-0002-5598-062X)
- Xuesong He
- Yaohua Fan (ORCID: https://orcid.org/0000-0002-1536-1904)
- Mingsheng Zhang (ORCID: https://orcid.org/0000-0002-8929-9349)
- Dongjuan Wu (ORCID: https://orcid.org/0000-0001-6191-0735)
- Chenxi Cao
Institutions
- Jiaxing University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1598436
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05